14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:JUNO
Delisted

Juno Therapeutics Fund Signals

$86.96
+0 (+0%)
At Close: Mar 28, 2018

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 2.360 27 days ( -2.33 % )
Last Price $86.96 0 %
High/ Low $86.96 - $86.96 0%
Chg 7 Days N/A $86.96 $86.96
Chg 30 Days 0.416 % $86.60 $86.96
Chg 12 mos 314.69 % $20.97 $86.96
Trend - 3 mos 50.01 % Width: 46.08 %
Trend - 12 mos 251.86 % Width: 64.67 %
Pred. range - 3 mos $115.13 - $168.18 32.39 % - 93.40 %
Pred. range - 12 mos $209.68 - $345.29 141.13 % - 297.07 %
Short MA avg 3 mos Sell Mar 12, 2018 - 13 days
Long MA avg 3 mos Buy Jan 16, 2018 - 51 days
Short/Long MA avg 3 mos Buy Jan 16, 2018 - 51 days
Short MA avg 12 mos Sell Mar 19, 2018 - 8 days
Long MA avg 12 mos Sell Jan 12, 2018 - 53 days
Short/Long MA avg 12 mos Buy Jan 03, 2018 - 60 days
Pivot Short Sell Mar 27, 2018 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Juno Therapeutics

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cel... JUNO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT